Workflow
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed CervoMed (US:CRVO) Globenewswireยท2025-05-12 12:00

Core Insights - CervoMed Inc. reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, indicating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) [1][2] - The company plans to initiate a Phase 3 trial of neflamapimod in DLB in mid-2026 after discussions with regulatory authorities [1][2] - CervoMed is also starting separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and those recovering from ischemic stroke [1][2] Recent Highlights and Anticipated Milestones - The 16-week results from the RewinD-LB trial showed a significant improvement in the Clinical Dementia Rating Sum of Boxes (CDR-SB) with p<0.001 compared to old capsules and p=0.003 versus placebo [4] - Full results were presented at the 19th International Conference on Alzheimer's and Parkinson's Diseases in April 2025, with 32-week results expected in the second half of 2025 [4] - Initial safety and pharmacokinetic data from an ongoing trial in patients with mild-to-moderate DLB are anticipated in Q4 2025 [4] Financial Overview - As of March 31, 2025, CervoMed had approximately $35.2 million in cash and marketable securities, down from $38.9 million at the end of 2024 [4][5] - Grant revenue for Q1 2025 was approximately $1.9 million, a decrease from $2.3 million in the same period in 2024, attributed to the transition of the RewinD-LB trial [6] - Research and development expenses increased to approximately $4.8 million in Q1 2025 from $2.8 million in 2024, driven by various clinical activities [7] Operational Metrics - General and administrative expenses rose to approximately $2.4 million in Q1 2025 from $2.1 million in the same period in 2024 [8] - The net loss for Q1 2025 was approximately $4.9 million, compared to a net loss of approximately $2.5 million in Q1 2024 [8][16] - The company reported a net loss per share of $0.56 for Q1 2025, compared to $0.41 for the same period in 2024 [16]